oru.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer
Show others and affiliations
2008 (English)In: Journal of the National Cancer Institute, ISSN 0027-8874, E-ISSN 1460-2105, Vol. 100, no 11, p. 815-825Article in journal (Refereed) Published
Abstract [en]

BACKGROUND: The majority of prostate cancers harbor gene fusions of the 5'-untranslated region of the androgen-regulated transmembrane protease serine 2 (TMPRSS2) promoter with erythroblast transformation-specific transcription factor family members. The common fusion between TMPRESS2 and v-ets erythroblastosis virus E26 oncogene homolog (avian) (ERG) is associated with a more aggressive clinical phenotype, implying the existence of a distinct subclass of prostate cancer defined by this fusion. METHODS: We used complementary DNA-mediated annealing, selection, ligation, and extension to determine the expression profiles of 6144 transcriptionally informative genes in archived biopsy samples from 455 prostate cancer patients in the Swedish Watchful Waiting cohort (1987-1999) and the United States-based Physicians(') Health Study cohort (1983-2003). A gene expression signature for prostate cancers with the TMPRSS2-ERG fusion was determined using partitioning and classification models and used in computational functional analysis. Cell proliferation and TMPRSS2-ERG expression in androgen receptor-negative (NCI-H660) prostate cancer cells after treatment with vehicle or estrogenic compounds were assessed by viability assays and quantitative polymerase chain reaction, respectively. All statistical tests were two-sided. RESULTS: We identified an 87-gene expression signature that distinguishes TMPRSS2-ERG fusion prostate cancer as a discrete molecular entity (area under the curve = 0.80, 95% confidence interval [CI] = 0.792 to 0.81; P < .001). Computational analysis suggested that this fusion signature was associated with estrogen receptor (ER) signaling. Viability of NCI-H660 cells decreased after treatment with estrogen (viability normalized to day 0, estrogen vs vehicle at day 8, mean = 2.04 vs 3.40, difference = 1.36, 95% CI = 1.12 to 1.62) or ERbeta agonist (ERbeta agonist vs vehicle at day 8, mean = 1.86 vs 3.40, difference = 1.54, 95% CI = 1.39 to 1.69) but increased after ERalpha agonist treatment (ERalpha agonist vs vehicle at day 8, mean = 4.36 vs 3.40, difference = 0.96, 95% CI = 0.68 to 1.23). Similarly, expression of TMPRSS2-ERG decreased after ERbeta agonist treatment (fold change over internal control, ERbeta agonist vs vehicle at 24 hours, NCI-H660, mean = 0.57- vs 1.0-fold, difference = 0.43-fold, 95% CI = 0.29- to 0.57-fold) and increased after ERalpha agonist treatment (ERalpha agonist vs vehicle at 24 hours, mean = 5.63- vs 1.0-fold, difference = 4.63-fold, 95% CI = 4.34- to 4.92-fold). CONCLUSIONS: TMPRSS2-ERG fusion prostate cancer is a distinct molecular subclass. TMPRSS2-ERG expression is regulated by a novel ER-dependent mechanism.

Place, publisher, year, edition, pages
Oxford: Oxford univ. press , 2008. Vol. 100, no 11, p. 815-825
Keywords [en]
Antineoplastic Agents; Hormonal/*pharmacology/therapeutic use, Area Under Curve, Blotting; Western, Cell Line; Tumor, Cell Survival/drug effects, Chromatin Immunoprecipitation, DNA; Complementary/metabolism, Estradiol/pharmacology, Estrogen Receptor alpha/*antagonists & inhibitors/metabolism, Estrogen Receptor beta/*agonists/metabolism, Estrogens/*metabolism, Gene Expression Profiling, Gene Expression Regulation; Neoplastic/drug effects, Health Surveys, Humans, Male, Neoplasms; Hormone-Dependent/drug therapy/*metabolism/pathology, Nitriles/pharmacology, Oncogene Proteins; Fusion/*metabolism, Physicians/statistics & numerical data, Polymerase Chain Reaction, Propionates/pharmacology, Prostatic Neoplasms/drug therapy/*metabolism/pathology, Pyrazoles/pharmacology, Serine Endopeptidases/metabolism, Signal Transduction/drug effects, Sweden/epidemiology, Transfection
National Category
Medical and Health Sciences Cancer and Oncology Urology and Nephrology
Research subject
Oncology
Identifiers
URN: urn:nbn:se:oru:diva-3670DOI: 10.1093/jnci/djn150PubMedID: 18505969OAI: oai:DiVA.org:oru-3670DiVA, id: diva2:137968
Available from: 2008-12-17 Created: 2008-12-17 Last updated: 2017-12-14Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedhttp://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Retrieve&list_uids=18505969&dopt=Citation

Authority records BETA

Andrén, OveFall, KatjaAndersson, Swen-OlofJohansson, Jan-Erik

Search in DiVA

By author/editor
Andrén, OveFall, KatjaAndersson, Swen-OlofJohansson, Jan-Erik
By organisation
School of Health and Medical Sciences
In the same journal
Journal of the National Cancer Institute
Medical and Health SciencesCancer and OncologyUrology and Nephrology

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 323 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf